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Background: Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might
participate given reasonable access.
Methods: A hierarchical approach is utilized in measuring staged participation from trial availability to patient
enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical
trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely
on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in
prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an
initial six month consultation are tracked from one stage to the next by race using the framework to assess
participation comparability.
Results: We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of
prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest
transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45%
patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%.
The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial
availability, patient interest and patient consented were three transitions that were below the average; none were
statistically significant.
Conclusions: The framework may serve to streamline comprehensive reporting of clinical trial participation to the
benefit of patients and the ethical conduct of clinical trials.
Keywords: Justice, Beneficence, Respect for persons, Clinical trials, Clinical trial accrual, Prostate cancer, Barriers to
clinical trials, Disparities, FrameworkBackground
Enrollment in interventional therapeutic clinical trials
involves a small fraction of all patients who might
participate given reasonable access. On examining
patients with incident cancer in the USA [1], California,
USA [2] and Maryland, USA [3], less than 3% partici-
pated in available trials [4]. Moreover, patients who are
seen at a cancer center, are representative of neither the* Correspondence: nkanarek@jhsph.edu
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reproduction in any medium, provided the orpopulation nor cancer cases [4,5]. A large proportion of
government-sponsored trials are conducted at National
Cancer Institute (NCI) cancer centers [1], located such
that 45% of all Americans live within a reasonable travel
time [6], and among patients who attend these cancer
centers, a higher proportion of cancer patients partici-
pate [2,7]. Once seen at a cancer center, the proportion
of those for whom the physician would recommend a
trial, for whom a trial is available, and for whom trial eli-
gibility criteria are met is about 25% [8]. Nevertheless,
enrollment may be improved as we learn more about
barriers to participation.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trials. Prior research has reported system, institution,
physician, and patient domains that merit attention
when trying to improve participation [9,10]. These same
domains may differentially affect access to clinical trials
for subpopulations [11,12]. Institutional investigations
may attempt to improve specific trial accrual, accrual
across all populations and cancer sites, or for specific pa-
tient groups [13,14].
A scan of the literature has identified several stages of ac-
crual to clinical trials. These stages include: trial availability
[15,16], study eligibility [17], physician triage (preference
or judgment about care outside the parameters of the trial
requirements) [15,16,18], presentation of the trial(s) [18],
determination of patient interest and barriers [15,19], and
acquisition of informed consent and enrollment [13]. In
the same literature sources, the ordering of stages differs,
or stages are combined. For instance, some investigators
engage physician triage first and then determine if the
patient’s condition fits any available trial. In another case,
trial availability and eligibility are conflated [8]. To date, a
hierarchical approach with transitional probabilities is
universally used though the order of accrual stage dif-
fers. Meanwhile, reporting differences make comparisons
difficult.
The ethical conduct of research in human subjects, in-
cluding the process of recruitment to clinical trials, is
the responsibility of trial principal investigator(s) (PIs)
and Institutional Review Boards (IRBs). While PIs are ul-
timately responsible for how they conduct their research,
local IRBs are responsible for review and oversight of all
human subject research conducted at their institution.
The ethical review conducted by IRBs is guided by three
principles: respect for persons, beneficence and justice
[19]. In practice, these principles focus the attention of
the IRB on assuring that the proposed trial will further
knowledge, be methodologically sound, have fair selec-
tion practices, possess a favorable risk-benefit ratio, be
judged by those independent of the study team, include
information on how the investigators plan to obtain
informed consent, and assure mechanisms are in place
respect individuals and their privacy [20].
In this paper we propose an ordered and comprehen-
sive set of accrual stages that are supported by ethical
considerations and comprise concepts reported in the
literature to date. These steps are illustrated with data
from a chart review of new prostate cancer cases seen in
medical oncology for six months.
Methods
Prostate cancer patients seen by three senior medical
oncologists for a first visit between January and April
2010 were studied (n = 94). Patient information was
gleaned from patient records and supplemented by theJohns Hopkins Hospital Cancer Registry. Any clinical
trial participation during the subsequent six months was
abstracted. These 94 prostate cancer cases represent
68% of all new Genito-Urinary Program consultations in
medical oncology during this period. Overall patient en-
rollment is the number of enrollees divided by all
patients presenting. Race-specific enrollment is delim-
ited by specific race or ethnicity.
Transitional probabilities (percentage in the current
step of those in the prior step) were calculated. To
summarize all transition probabilities, we calculated the
overall seven-step transitional probability by taking the
seventh root of the overall enrollment percentage of all
patients. Three multistep transition probabilities were
also calculated (multiplicands of component transitional
probabilities).
The chi square test for independence was used to
evaluate demographics of those eligible/not eligible in
the case series and those enrolled/not enrolled; none
reached statistical significance in this pilot and small
sample size series.
The Clinical Research Office at the Sidney Kimmel
Comprehensive Cancer Center (SKCCC) reviewed and
approved the study.
Patient to accrual framework
As noted earlier, ethical clinical trial enrollment is made
up of 1) scientific oversight, 2) trial availability, 3) patient
eligibility, 4) physician triage, 5) discussion of trials, 6) as-
certainment of patient interest and willingness to partici-
pate in a particular trial, 7) consent for participation, and
8) enrollment. Each of these eight important steps is
implicitly or explicitly a consideration in enrollment of
patients into clinical trials. We suggest that there is an
ethical hierarchy, that is, each step must be fulfilled before
proceeding to the next step to fulfill obligations to provide
trials embodying justice, beneficence, and autonomy [19].
Scientific oversight
Scientific oversight is the responsibility and the domain of
the institution. Trials are designed, reviewed, approved
and joined with the goal of gaining generalizable know-
ledge about whether treatment is better than current mo-
dalities, and as proposed, the study has benefits to future
patients and may have benefits to those in the trial (ben-
eficence). Impediments to trial participation at this stage
are that the institution cannot identify patients who will
benefit, that patients do not attend the institutions where
the trials are offered, or that the institution cannot launch
trials efficiently. This strikes at the heart of clinical trial
performance - failure to accrue [21]. Enrollment of suffi-
cient subjects is often the basis for multi-center trials
when no one institution can possibly enroll enough
patients in the optimal time window. Hereafter, we assume
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generalizable knowledge using rigorous methods and mon-
itored by independent scientific oversight (Table 1).
Trial availability by disease characteristics
Trial availability by disease characteristics is both an insti-
tutional and an investigator domain. Availability of a trial
is defined as: a trial exists that is open, actively enrolling
patients, and appropriate to the patient’s condition (for ex-
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Patient enrollment Investigator 7-Respect for enrolled
subjectsBroadly, availability measures the ability to serve a signifi-
cant proportion of the patients who enter that research
institution and ethically measures fair distribution (justice)
of risks, benefits and costs. From prior reports, trial avail-
ability is usually the primary barrier to participation in
clinical trials [15,16].
Eligibility
Eligibility is an investigator domain and is managed in trial
design. Eligibility for a trial is determined by the actualtrials by domain and ethical factors
inciples Sample reasons for not participating in a clinical trial
[15,22,41,52]
e Cannot identify patients
Patients seek services elsewhere
Cannot enroll enough patients
Unavailability
No measureable/confirmable disease
No testable treatments for the disease, stage, or other
characteristics
Prior tumor, second cancer, metastases
Precluded by prior or current treatment or co-morbid
conditions
e Poor performance status
Asymptomatic
Study demands
Treatment not tolerated, died soon, disease is too advanced
Quality of life issues
Life expectancy is limited
Need for immediate treatment
Physician preference/judgment
r Physician judged compliance issues
Doctor-patient communication issues
r Treatment preference /placebo
Minimal care: symptomatic treatment only, supportive or
hospice care desired, refused further staging
Not interested
Barriers: distant from clinic [5], financial, insurance [48],
personal circumstances
Second opinion only, return to home physician, no ongoing
relationship
r Fear of randomization
Fear of side effects
Negative aspects of a trial participation, distance
Patient failed trial screening protocol
Withdrawal
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defined patient determinants (for example, risk [12], prior
treatment [24]) or a person’s ability to meet the participa-
tion requirements of the trial (for example, follow-up at-
tendance). To avoid doing harm (beneficence) and to
implement fair subject selection criteria (justice), eligibility
is established for each trial. In the case of early-phase
trials, criteria are designed to predict tolerance of the
maximum dose and are often characterized by comorbid-
ities, biologic measures of functioning (for example, red
blood count), drug tolerance, prognosis, and with judi-
ciousness, by patient demographics [25-27].
Physician triage
Physician triage [26] is the domain of the patient’s doc-
tor. The treating and consulting physicians, whether it is
the primary-care provider or cancer specialist, makes
decisions about patient suitability for clinical trials in
order to minimize harm. A patient who is inaccurately
assessed as eligible could be harmed by enrollment (lack
of beneficence). Physicians who know the patient can
make decisions about whether for particular patients a
reasonable risk-benefit balance is not met as judged by
quality of life and life expectancy information, whether
the patient requires immediate treatment, or whether
deference for a person’s last days, or their decision to
treat no further should hold sway. Physician presump-
tion about the patient’s ability or willingness to partici-
pate (for example, based on age or distance from the
clinic) is sometimes reported in this category [26]. While
physicians may have knowledge about these potentially
real barriers to participation in trials, we suggest phys-
ician presumptions should be assiduously avoided at this
stage [27]. This step involves a therapeutic orientation,
which is concern for the person as patient in contrast to
study subject [28].
Patient-trial fit
Patient-trial fit is the percentage of all patients for whom
there is a trial available, eligibility requirements are met,
and the physician has deemed the patient a trial candi-
date. Patient-trial fit is in the domains of institution,
investigators, and physician and is a comprehensive meas-
ure of the match of the institutional trial portfolio, and its
clientele. The ethics of justice and beneficence are demon-
strated here.
Discussion of trials
Discussion of trials between the treating physician and
the patient is most often in the physician domain to ini-
tiate [29-31], though more and more frequently patients
raise the possibility with their doctors, the patient do-
main [32,33], and this is increasingly recognized as
physician-patient partnership [34,35]. Discussion of trialsoccurs to ascertain whether a patient is able to under-
stand the nature of the clinical trial [36,37] and its bene-
fits and costs, and to assess the patient’s ability to
provide informed consent [38]. It is also a significant
recognition that patient autonomy is a value that to act
upon entails allowing each patient to decide about trial
participation to the extent of their ability. In the past
and especially for community physicians, convenience,
cost, and necessary follow-up visits in addition to age
were perceived as barriers for their patients and so trials
were not discussed [13,39]. Go and colleagues [15] de-
scribe as reality that about a quarter of community phy-
sicians think risks outweigh benefits at this stage and do
not discuss trials with their patients - a clear and rele-
vant factor in physician triage. Discussion of a trial with
every patient for whom there is patient-trial fit, however,
respects each person and their decision making.
Patient interest and willingness
Patient interest and willingness in participation in a
clinical trial is in the patient domain (including family
members and caregivers). The majority of cancer
patients are unaware that they might be eligible for a
clinical trial, or that trials are conducted where they are
receiving treatment [10]. Interest in a trial is predicated
on respect for persons and may be associated with opti-
mism [40], gender [41], more information (cancer site,
age > 80 years, serious disease status) [13,32,33,38], type
of intervention, marital status, race [42], physician com-
munication styles [43], and other factors [27].
Opportunity
Opportunity is the percentage of those patients who fit
the criteria for trial inclusion, who are interested in and
willing to participate in a clinical trial. Opportunity is in
the domains of both the physician and patient and is an
aggregate measure of providing the option of trial par-
ticipation among those for whom there is a trial that fits
their characteristics and embodies the ethic of respect
for persons.
Patient consent
Patient consent is a domain stage of clinical trial accrual
and is linked closely to respect for patient autonomy
[34,44]. Issues related to prostate cancer participation in
clinical trials that facilitate consent include patient prefer-
ences for specific interventions [45], lower socioeconomic
status [46], cost of travel and friends/family to accompany
the patient [43,47], availability of the intervention outside
a trial setting [48], and an intervention that ‘kills cancer
cells’ [49]. Under some circumstances, parents, guardians,
or family may have an important consent or support role.
In the study of other diseases additional factors may be
found to affect patient consent.
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Patient enrollment is in the study investigator domain
and assesses whether the patient meets the specific study
requirements at the time of enrollment, and then begins
care in the clinical trial. Impediments at this point may
include lack of insurance coverage [8,18,50], staff sup-
port, and timely participation slots.
Acceptance
Acceptance is the percentage of interested and willing
patients with whom a trial was discussed, who accept a
clinical trial, and are accepted into a clinical trial. Ac-
ceptance is a measure of patient enrollment once trial-
patient fit and opportunity are confirmed.
Results
We illustrated seven transitions from being a patient to
enrollment in a clinical trial in a small pilot study of about
a hundred prostate cancer cases who consulted SKCCC
Medical Oncology Department in early 2010. Figure 1
illustrates accrual stages 2 to 8 in a sample of prostate
cancer patients seen for a first visit by three experienced
medical oncologists and followed for 6 months. At each
stage of accrual, patients are categorized from trialFigure 1 Flow chart of prostate cancer patient enrollment in medical
Comprehensive Cancer Center.availability to enrollment. Percentages in parentheses are
transitional probabilities based on the number of patients
available at the previous stage. In Figure 1, we illustrate
the reasons given for not continuing toward enrollment at
each stage.Clinical trial enrollment
Of the 94 patients seeking care, 11 were enrolled in
medical oncology clinical trials. The white enrollment
rate was 10% (8/78), black enrollment was 27% (3/11),
and enrollment among other races and Hispanic ethni-
city was 0% (0/5).Transition probabilities
We obtained transitional probabilities as follows: 65%
(61/94) availability, 84% (51/61) eligibility, 92% (47/51)
physician triage, 89% (42/47) trials discussed, 45% (19/
42) patient interested, 63% (12/19) patient consented,
and 92% (11/12) patient enrolled. The average transi-
tional probability was 74%. The aggregate transitional
probability, patient-trial fit was 50% (47/94); opportunity
was 40% (19/47), and acceptance was 58% (11/19). Trial
availability, patient interested and patient consentedoncology clinical trials, January to April 2010, Sidney Kimmel
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none was statistically significant.
Reasons for drop-off
We categorized drop-off from stage to stage. Of the
thirty-three patients who were not eligible for a trial, six
(18%) had pre-recurrent disease, fourteen (42%) had re-
current prostate cancer, and eleven (33%) had metastases.
Two patients (6%) had not had enough information to
classify them by condition. Ten patients were not trial-
eligible; of these, one (10%) had a second cancer, one
(10%) had received chemotherapy, and eight (80%) had
low or non-rising prostate-specific antigen (PSA) levels. In
the physician triage category, a physician determined that
one patient (25%) needed immediate treatment, one had a
job whose requirements ruled out participation, one was a
patient for whom distance would be a problem (inter-
national patient), and one was not a good trial candidate.
Eighty-nine percent of patients triaged had trials discussed
and the remaining eleven percent were recommended a
standard therapy or continuation of their current regimen.
Nineteen of the 42 patients were interested when informed
about clinical trials, and 23 (49%) were not interested. The
reasons for lack of interest or willingness to participate
were two-fold: distance was a problem for 19 patients
(83%) and four preferred a specific treatment. Of those
nineteen patients interested in trials, one (14%) was bound
by actual and six (86%) by psychological distance of having
a referring physician to return to. Of the patients who con-
sented, one of the eleven (8%) failed the pre-enrollment
screening protocol.
Drop-off between patient consultations and patient-trial
fit was 47 patients; 70% (33/47) had no trial available, 21%
were not eligible (10/47), and 9% (4/47) were not triaged.
The drop-off to opportunity was five patients, which was
made up entirely of patient’s lack of interest or doctor’s
recommendation to continue with standard of care, and
drop-off to acceptance was eight patients, made up of
seven patients (88%) who did not consent and one (12%)
who failed to meet the requirements of the study protocol.
Patient subgroups
To illustrate how this framework might be used to track
enrollment of patient subgroups, we show patients by race
and ethnicity in Figure 1. Noting that this case series is
based on a relatively small number, we do not report stat-
istical significance. More than half of white patients
dropped off over the patient-trial fit, while 20% of black
patients dropped out at eligibility and at enrollment. The
sole Hispanic patient was not interested in a trial.
Discussion
Despite small numbers, this analytic, framework approach
has given our cancer center a basis for troubleshootingclinical trial accrual for individuals of specific race or His-
panic ethnicity or other patient characteristics, although
larger samples are necessary to assess this statistically. The
approach has highlighted that trial availability and patient
interest and consent are areas of potential improvement.
To actually make improvements, more information may
be necessary and a prospective, more real-time approach
would be useful.
We believe our proposed order of transitions is endorsed
by a number of ethical principles. Placing physician triage
after availability and eligibility instead of before assures that
the process is just. That is, subject eligibility is based on a
systematic process utilizing objective criteria rather than
relying on each physician’s ability to recall the criteria for
each open trial for which a patient may be eligible. This ap-
proach also promotes the principle of beneficence by mak-
ing sure that all who may benefit from enrollment are
identified. In addition, our categorizing of the patients who
were dropped out of consideration for a clinical trial also
assures the process is just [51-53]. Moreover, this approach
clarifies the basis for exclusion. No doubt additional
reasons will be added to our list, and this may be accom-
plished with the help of the principles that guide any par-
ticular transition. Our emphasis on making certain that the
trial is adequately described to the patient and discussed
with the patient, signifies a respect for a patient’s right to
choose and is the basis for shared information.
The proper first stage as described is establishing sci-
entific oversight for a clinical trial enterprise. This stage
is not to be underestimated in importance, but it is not
generally a hurdle for a medical research institution that
has established the necessary infrastructure to identify
patients and maintain efficient approval of studies. Avail-
ability of clinical trials may be considered a measure
of effectiveness at cancer centers, whose charge is to
provide a broad portfolio of clinical trials for the patients
it serves.
Seven transitions may be more than necessary and we
have suggested a consolidation of transitional probabil-
ities. These may be the key to standardization across
studies, while reserving all seven for problem-solving
within a study, a program or an institution. We think a
systematic approach to therapeutic trials accrual will
create uniform reporting and reduce physician triage of
patients whom they judge ineligible, that is, unable to
participate for various reasons. Investigators at other
academic cancer centers have observed higher patient
interest (84%) when physician perception of eligibility
was implemented first, and that this combined with trial
availability eliminated two thirds of all patients before
interest was ascertained [13]. In a community-based can-
cer center, Go and colleagues [15] found the proportion
of patients for whom a trial was available similar to the
one observed in this pilot (66% as compared to 65%).
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ies, as standardized reporting and more importantly,
standardized hierarchy of accrual to trials has not been
available. In reporting to the NCI, standardization makes
good sense, gives NCI cancer centers benchmarks, and
highlights potential unique issues at each center. An issue
highlighted by this analysis is distance from the center.
One physician judged it an issue, nineteen patients cited it
as a reason they were not interested, and one patient as
the reason they could not consent. This totals 21 of the
original 94 patients (22%) for whom there were trials; phy-
sicians thought they were good candidates and the patient
was eligible, but distance was a problem, yet for different
reasons that may have different remedies.
Again, this framework provides information for problem-
solving and improving clinical trial participation by domain
and by steps to accrual. Patient interest seemed to be a
weak point in accrual but the primary reason for not par-
ticipating might be totally understandable - distance from
the cancer center (79% were not from Maryland). We
would contrast this with 88% of accruals to trials being
non-Maryland residents, so consideration of distance as a
trial availability or eligibility criterion should be done with
caution. Accruers may be those individuals who come to a
regional cancer center in order to participate in trials [5].
Conclusions
Examination of these transitions by domain points out
that accrual to therapeutic trials may be enhanced with
institutional/systemic attention to trial availability and
eligibility, physician responsibilities to care for a patient
and enroll them in clinical trials, and attention to patient
interest and consent. In addition to distance, treatment
preference is a potentially important reason for no inter-
est in a trial, as is continuing care with their referring
physician, for not consenting to a trial. These findings
point out that trials closer to home or those with the in-
volvement of the referring physicians may be the best
solution. Reassuringly, this sampling of patients indicates
the dedication of medical oncology clinical trialists to
the steps of discussion and enrollment in trials. Still, this
is just one cancer site and one treatment program.
Abstraction of patient flow periodically would aid in
continuously tracking and troubleshooting clinical trial
accrual. For instance, minimal eligibility criteria and
requirements of clinical trial participation when possible,
may promote more eligible candidates at the outset and
consideration of a trial at ascertainment of patient inter-
est. A continuous feedback loop of information for sus-
taining the pipeline of clinical trials for a broad spectrum
of patients would be another possible aspect of data col-
lection and analysis. To put these findings into action, we
will design a trials data collection form/computer module
that will organize screening for trials and facilitatediscussion of trials and eligibility with new patients
within the cancer program. This pilot study has provided
sufficient information to apply this tool in our clinics.
While taking every patient through every step may
entail some additional time, it assures that patient au-
tonomy will be preserved and opportunity to participate
will be maximized. Beyond patient interest these data
point out what has been reported elsewhere: trial avail-
ability and eligibility are important considerations for
improving accrual and access for many.
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